|
 |
PPD, SRI sign agreement for vax clinical research services
 |
|
| PPD and Southern Research Institute (SRI) have formed a collaborative agreement in pandemic and seasonal influenza vaccine research and development to provide clients a full spectrum of influenza vaccine development services by collaborating on clien |
|
 |
|
|
| |
| Sun Pharma bags FDA Approval for Prometh syrup
|
|
| Sun Pharmaceutical announced that the USFDA has granted its subsidiary an approval for its ANDA for Promethazine Hydrochloride and Codeine Phosphate Oral Syrup, 6.25 mg/5 ml and 10mg/5ml |
|
|
|
|
| |
| Elder Pharma hikes stake in Bulgarian acquisition to 61%
|
|
| Elder Pharmaceuticals, manufacturer of Shelcal, has extended its control over its Bulgarian acquisitions by hiking stake in its Bulgarian subsidiary, Elder Biomeda, to 61 percent from the present 51 percent for an undisclosed sum |
|
|
|
|
| |
|
|
| |
|
|
| |
| Quintiles announces new Central Lab in Japan
|
|
| Quintiles, a fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide has successfully relocated its Global Central Laboratory in Japan from Saitama to Tokyo to allow for expansion |
|
|
|
|
| |
| ICON to open new office in Manila
|
|
| ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced that it will expand its footprint in Asia-Pacific with the opening of an office in Manila, Philippines |
|
|
|
|
| |
| WHO suspends use of Shan5 due to quality issue
|
|
| The World Health Organization (WHO) has suspended procurement and use of Shan5 vaccine made by India's Shantha Biotechnics, owned by France's Sanofi Aventis. The recommendation by WHO came March 12 |
|
|
|
|
| |
| GVK BIO opens new clinical pharmacology unit in India
|
|
| GVK Biosciences, one of the Asia's leading contract research organizations, has commissioned its new clinical pharmacology unit (CPU) in Ahmedabad, India. The Ahmedabad CPU adds 110 beds to GVK BIO's existing capacity of 144 beds |
|
|
|
|
| |
| Abbott announces +ve data from ABSORB trial
|
|
| Abbott announced positive 30-day results from the first 101 patients enrolled in the second phase of the ABSORB trial. Patients treated with Abbott's bioresorbable vascular scaffold (BVS), under clinical investigation in Europe, demonstrated no cases |
|
|
|
|
| More |
